The Medios Individualised Medicines from Medios AG - compounding service keeps rare patients supplied

Reviewed: ad hoc news Bestseller & Flagship desk. Edited and checked on 2026-06-29, 08:31. Details in the imprint.

The Medios Individualised Medicines compounding service starts where standard tablets and blister packs fail. In a quiet back room of a partner pharmacy, you can almost smell the alcohol swabs as a technician weighs micro doses for a child with a rare cancer.

What Medios actually offers

Medios Individualised Medicines is the compounding and therapy-accompanying service Medios AG markets to specialty pharmacies caring for chronically and oncology patients. The company positions itself as a pharma service provider focusing on complex therapies and rare diseases in Germany.

Instead of a single flagship pill, Medios builds a portfolio of tailored preparations, documentation services and logistics solutions that sit behind the pharmacy counter. For doctors and pharmacists, this turns the firm into an outsourced back office for difficult prescriptions that standard wholesalers do not handle well.

How the service works day to day

In practice, Medios Individualised Medicines means that when an oncologist writes a dosing schedule that does not match any ready-made pack size, a Medios partner pharmacy can forward the order into the compounding workflow. There, trained specialists prepare capsules, solutions or suspensions exactly to the protocol.

Every batch is documented and labeled so that the pharmacist can hand the medicine over with traceability and quality checks recorded, rather than improvising in-house. For a mother standing at the pharmacy counter, this can feel like a safety net - she sees a clean, clearly printed label instead of a hand-written sticker.

Why rare-disease care needs this

Germany’s hospital and pharmacy system is still heavily built around standard pack sizes and industrial batches, which works for hypertension or antibiotics but not for fine-tuned oncology or enzyme replacement therapies. A child who weighs 18 kilograms may need a micro-dose that no standard vial matches.

Medios Individualised Medicines fills that gap by scaling up centralised compounding instead of leaving each individual pharmacy to improvise at the bench. In effect, this moves a fragile process into a controlled environment designed for this one purpose, from raw-material sourcing to temperature-controlled shipping.

Faces behind the service

Medios chief executive Matthias Gärtner likes to frame the company’s offering as an ecosystem for specialty pharma rather than a classic drugmaker. In interviews, he repeats that the firm does not push its own brand on patients but focuses on reliable supply and documentation for partner pharmacies.

A clinical pharmacist like Dr. Anna Schulz in a Berlin oncology center will notice the difference mainly in her workflow. Instead of phoning multiple wholesalers, she keys the order into a single interface and receives an individualised preparation with the necessary paperwork attached.

Strengths and friction points

The biggest strength of Medios Individualised Medicines is the combination of centralised scale and local partners. Pharmacies keep their patient-facing role, while Medios takes over the technically demanding part in the background. That division lets smaller pharmacies stay in complex therapies without running their own full lab.

The flipside is dependency. If a partner pharmacy leans heavily on Medios and a shipment is delayed, there is little plan B at hand. Patients used to seeing a neat white box with a Medios-prepared label may feel unsettled if the pharmacist suddenly has to improvise another solution.

How investors should place it

All told, Medios Individualised Medicines is less a single hero product than a backbone service in the company’s strategy to grow with complex therapies and rare-disease patients. For retail investors, it matters because the service builds recurring relationships with pharmacies rather than one-off drug launches.

Medios shares (ISIN DE000A1MMCC8) are listed in Germany, and the company presents itself as a specialty pharma platform rather than a classical manufacturer, which shapes how analysts look at growth and margins.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | DE000A1MMCC8 | MEDIOS | boerse | 69650469 | bgmi